Asthma

ANDHI study - Astra-Zeneca (52 week)

Principle Investigator:
Dr Monica Nordstrom

Double-blind placebo controlled study to assess the efficacy and safety of Benralizumab (anti-eosinophilic injection) in patients with uncontrolled asthma who have eosinophils >150 cells/ microliter (0.15). Non-smokers (<10 pack-years) 2 exacerbations, FEV1 pre BD <80%

LUSTER study - Novartis – Fevipiprant – Th2- antagonist – anti-eosinophilic tablet – 52 weeks with extension into the Spirit study

Principle Investigator:
Dr Monica Nordstrom

Double-blind placebo-controlled, eosinophils >250 cells/microliter (0.25), 2 exacerbations, FEV1

SPIRIT- Novartis - Fevipiprant – Th2- antagonist – anti-eosinophilic tablet up to 3 years

Principle Investigator:
Dr Monica Nordstrom

Double-blind placebo-controlled, pre BD FEV1

 

COPD

PEARL – Astra-Zeneca

Principle Investigator:
Dr Monica Nordstrom

Double blind- placebo controlled trial. A further development of the Symbicort inhaler and must have had 2 exacerbations with Pred, smokers, >20 pack- years, 52 weeks.

 

Bronchiectasis

 

Comng soon.